MEF2 transcription factors are well-established regulators of muscle development. We have discovered an unanticipated role for MEF2C in the neural crest, where tissue-specific inactivation results in neonatal lethality due to severe craniofacial defects. We show that MEF2C is required for expression of the Dlx5, Dlx6, and Hand2 transcription factor genes in the branchial arches, and we identify a branchial archspecific enhancer in the Dlx5/6 locus, which is activated synergistically by MEF2C and Dlx5, demonstrating that these factors interact to induce transcription. Mef2c and Dlx5/6 also interact genetically. Mice heterozygous for either Dlx5/6 or Mef2c are normal at birth and survive to weaning. By contrast, heterozygosity for both Mef2c and Dlx5/6 results in defective palate development and neonatal lethality. Taken together, the studies presented here define a feed-forward transcriptional circuit between the MADS-box transcription factor MEF2C and the homeodomain transcription factors Dlx5 and Dlx6 in craniofacial development.
INTRODUCTION
Neural crest (NC) cells originate from the dorsal neural tube at the border between the neural plate and the lateral epidermis (Knecht and Bronner-Fraser, 2002; Trainor, 2005) . When induced by contact-mediated signals, NC precursor cells undergo an epithelial-to-mesenchymal transition, migrate throughout the developing embryo, and give rise to various tissues, including the dorsal root and sympathetic ganglia, the glial cells of the peripheral and enteric nervous systems, melanocytes, and skeletal elements of the face and head (Knecht and BronnerFraser, 2002; Le Douarin et al., 2004; Trainor, 2005) . Numerous congenital disorders are due to improper development of the NC and its derivatives, including craniofacial defects, which account for one-third of all congenital anomalies (Farlie et al., 2004; Trainor, 2005) .
Several transcription factors are known to be required for craniofacial development (Cobourne, 2000; Depew et al., 2005) . Among these, the homeodomain transcription factors Dlx5 and Dlx6 are expressed in the NCderived ectomesenchyme of the first and second branchial arches, and inactivation of Dlx5 and Dlx6 results in mice that have numerous craniofacial defects (Beverdam et al., 2002; Depew et al., 2002) . Dlx6 is a direct transcriptional activator of the Hand2 gene, which encodes a basic helix-loop-helix (bHLH) transcription factor, in the first and second branchial arches via a conserved branchial arch enhancer element (Charite et al., 2001) . Hand2 enhancer null mice exhibit cleft palate and hypoplasia of the mandible, among other craniofacial malformations . It is known that expression of both Dlx6 and Hand2 in the branchial arch mesenchyme requires endothelin signaling, but other components of this pathway, including the transcription factors required for activation of Dlx5 and Dlx6, are unknown (Charite et al., 2001; Clouthier et al., 2000; Ruest et al., 2004; Thomas et al., 1998) .
The myocyte enhancer factor 2 (MEF2) family of transcription factors has four members in vertebrates, MEF2A-D (Black and Olson, 1998; McKinsey et al., 2002) . MEF2 proteins bind to a consensus DNA-binding element known as a MEF2 site as homo-and heterodimers and interact with other transcription factors to function as both positive and negative regulators of gene expression, in part through their association with class II histone deacetylases (HDACs) (McKinsey et al., 2001) . Mef2c is the first member of the MEF2 family to be expressed during development, and Mef2c null mice die at embryonic day 9.5 (E9.5) with severe defects in cardiac and vascular development (Edmondson et al., 1994; Lin et al., 1997 Lin et al., , 1998 . Although MEF2C is widely appreciated for its role in the development of muscle lineages, its expression adjacent to the neural folds at E8.5 in early NC development has been reported previously (Edmondson et al., 1994) , but its function in the NC has not been investigated.
In the present study, we used a conditional gene targeting approach in mice to inactivate Mef2c in the NC, which results in lethality at birth due to upper airway obstruction.
Mef2c NC knockout mice exhibit delayed ossification and hypoplasia or loss of the majority of the skeletal elements of the face and skull. We show that the transcription factor genes Dlx5, Dlx6, and Hand2 are not expressed in the NC component of the branchial arches in Mef2c NC conditional knockout embryos, and we identify a MEF2-dependent transcriptional enhancer in the Dlx5/6 locus that is sufficient to direct expression to the branchial arches in vivo, establishing MEF2C as a direct transcriptional regulator of the Dlx6-Hand2 pathway in the NC. Furthermore, the Dlx5/6 enhancer identified in these studies is activated synergistically by MEF2C and Dlx5, indicating that these factors interact to regulate transcription. We also show that Mef2c and Dlx5/6 interact genetically. Mice heterozygous for either Dlx5/6 or Mef2c are normal, whereas mice heterozygous for both Mef2c and Dlx5/6 do not survive and exhibit defective palate development. These studies highlight a previously unappreciated role for MEF2C in craniofacial development and identify a novel, feedforward transcriptional circuit between MEF2C and Dlx5/ 6 in craniofacial development.
RESULTS

Mice Lacking Mef2c Function in the Neural Crest Die at Birth Due to Upper Airway Obstruction
To determine the function of MEF2C in the NC, we conditionally inactivated a floxed allele of Mef2c by using Wnt1-Cre transgenic mice (Danielian et al., 1998; Vong et al., 2005) . Animals lacking Mef2c in the NC were born at expected Mendelian ratios and were animated and responsive to touch. However, Mef2c conditional knockout mice quickly became cyanotic, and 100% of these animals died within an hour of birth ( Figure 1A ).
The hearts, vasculature, and diaphragms of Mef2c NC null mice showed no differences in gross morphology, histology, or marker gene expression compared to control littermates (data not shown). However, neonates lacking Mef2c function in the NC exhibited a posterior cleft of the palate ( Figure 1B) , a constricted airway, and defective positioning of the tongue near the back of the oral cavity compared to control littermates ( Figures 1C and 1D ). These defects occurred with 100% penetrance in knockout animals (n = 63) and in none of the littermate controls. Knockout animals were tracheostomized with a 30G needle to bypass the upper airway, which resulted in recovery from cyanosis and restoration of viability prior to humane euthanasia (data not shown), demonstrating that mice lacking Mef2c in the NC die at birth from asphyxiation caused by upper airway obstruction.
Mef2c Function Is Required in the Neural Crest for Craniofacial Development Skulls from Mef2c NC conditional knockout neonates exhibited several defective or missing craniofacial structures, including a hypoplastic mandible, zygomatic arch, and temporal bone, compared to control littermates (Figure 1 and 1H). At E16.5, wild-type skulls displayed normal Meckel's cartilage and extensive ossification in the mandible and maxilla ( Figure 1I ). By contrast, Mef2c NC knockout embryos exhibited hypoplastic Meckel's cartilage and a lack of ossification, as well as hypoplasia of other future skeletal elements in the skull ( Figure 1J ). The differences in skeletal development could be observed as early as E13.5, a time prior to the onset of ossification, when Meckel's cartilage was already hypoplastic in conditional knockout animals (data not shown). Taken together, these results clearly establish that MEF2C function is required in the NC for proper craniofacial development.
Branchial Arch Expression of Dlx5, Dlx6, and Hand2 Requires MEF2C In order to place MEF2C into a pathway for craniofacial development, we examined the expression of several transcription factor genes required for craniofacial development at E9.5, which is the time when Mef2c is expressed in the NC component of the branchial arches and developing craniofacial mesenchyme (Figures 2A and 2B) . Notably, Dlx5, Dlx6, and Hand2 expression in the first and second branchial arches was almost completely absent in Mef2c NC knockout mice compared to control littermates at E9.5 (Figures 2C-2H; Figures S1A-S1D, see the Supplemental Data available with this article online). Prx1 null mice also have a similar craniofacial phenotype to Mef2c NC conditional mice (Martin et al., 1995) . However, no differences were observed in Prx1 expression in Mef2c NC knockout and control embryos (Figures S1E and S1F), indicating that branchial arch development in general was not defective at this stage, and that Prx1 is not a downstream target of MEF2C. No differences were observed in the Wnt1-Cre fate map between NC knockout and control embryos in a ROSA26R lacZ reporter background (Soriano, 1999) , indicating that the contribution of NC cells to the branchial arches and viscerocranium was not grossly defective (Figures 2I and 2J) . Likewise, no obvious changes were observed in proliferation or apoptosis between knockout and control embryos at E9.5 or E10.5 ( Figures S1G-S1J ). Taken together, these results suggest that the requirement for Mef2c is in the postmigratory NC, and that MEF2C is an upstream regulator of the Dlx6-Hand2 pathway in craniofacial development.
A Novel, Branchial Arch Enhancer from the Dlx5/6 Locus Is Directly Activated by MEF2C Dlx6 is closely linked to Dlx5 in the mouse genome (Zerucha et al., 2000) , and deletion of both genes results in very severe craniofacial defects. Inactivation of Dlx5/6 in mice results in loss of Hand2 expression in the branchial arches at E9.5, and Dlx6 has been shown to be a direct transcriptional regulator of Hand2 through a conserved enhancer in the Hand2 locus (Beverdam et al., 2002; Charite et al., 2001; Depew et al., 2002; Ruest et al., 2004) . Since Dlx5, Dlx6, and Hand2 were downregulated in the absence of Mef2c function in the NC, we hypothesized that MEF2C might directly regulate these genes. To identify potential transcriptional enhancers from these genes, we analyzed all of the conserved, noncoding sequences in the Dlx5/6 and Hand2 loci for MEF2 sites, and we identified a deeply conserved element immediately upstream of the Dlx6 coding sequence ( Figure 3A ) that contained four highly conserved MEF2 sites and multiple potential homeodomain protein (Hox)-binding sites ( Figure 3B ). We tested this region of the Dlx5/6 locus for enhancer activity by cloning it into the Hsp68-lacZ reporter plasmid and using this construct to generate transgenic embryos. This novel region of the Dlx5/6 locus directed expression to the first and second branchial arches at E9.5 ( Figure 3C ) in a pattern very similar to the endogenous Dlx5 and Dlx6 expression patterns in the arches ( Figures  2C and 2E ). All four of the candidate MEF2 sites in the Dlx5/6 locus were bound by MEF2C in EMSA, although only the MEF2-3 and MEF2-4 sites exhibited robust binding in vitro (data not shown). To determine if the Dlx6 enhancer was responsive to MEF2 activation via its conserved MEF2 sites, we tested a Dlx6-TK-lacZ reporter construct for MEF2C trans-activation in 3T3 cells ( Figure 3D ). Cotransfection with a MEF2C-VP16 expression plasmid resulted in 12-fold greater activation of the Dlx5/6 reporter than control cotransfections ( Figure 3D , lane 4), and this activation was dependent on the presence of intact MEF2 sites since mutation of the four sites resulted in a complete loss of activation of the enhancer element by MEF2C ( Figure 3D , lane 6). Taken together, these results demonstrate that the MEF2 sites in this novel Dlx5/6 branchial arch enhancer are functional and further support the notion that Dlx5 and Dlx6 are direct transcriptional targets of MEF2C via this enhancer element.
Cooperative Activation of the Dlx5/6 Branchial Arch Enhancer by MEF2C and Dlx5 The presence of multiple conserved Hox sites, combined with the presence of functional MEF2 sites in the Dlx5/6 branchial arch enhancer, suggested that this enhancer might also be activated by Dlx proteins themselves. We tested this possibility and the possibility that MEF2C might participate in a feed-forward transcriptional circuit with Dlx5/6 by activating their expression and then cooperating with them to amplify Dlx5/6 expression ( Figure 3E ). Indeed, Dlx5 activated expression of the Dlx5/6 enhancer more than 50-fold ( Figure 3E , lane 5). Furthermore, under conditions in which wild-type MEF2C activated the enhancer only 3-fold ( Figure 3E, lane 4) , cotransfection of Dlx5 and MEF2C resulted in clear synergy by activating reporter expression more than 400-fold ( Figure 3E , lane 6). (Depew et al., 2002) . Heterozygosity for either Mef2c or Dlx5/6 alone did not significantly affect neonatal viability ( Figure 4A ). By contrast, 100% of double heterozygous offspring were obviously sick at birth and died on postnatal day 0 (P0) (Figure 4A ), indicating a clear genetic interaction between the Dlx5/6 and Mef2c loci. Compared to wild-type littermates, Dlx5/6 +/À ;Mef2c +/À mice exhibited a small, incomplete palate and a displaced tongue ( Figures 4B and 4C) , which is consistent with the palate and displaced tongue phenotype in Mef2c NC conditional knockout mice ( Figure 1D) ; these results further support the conclusion that MEF2C functions as a transcriptional activator and partner of Dlx5 and Dlx6 in craniofacial development ( Figure 4D ).
Genetic Interaction between
DISCUSSION
A MEF2-Dependent Transcriptional Pathway for Craniofacial Development
We have uncovered a novel role for MEF2C function in the NC as an essential regulator of craniofacial development. The defects in Mef2c NC knockout mice are similar to those found in other transcription factor knockouts, including Prx1, Dlx5/6, and Hand2 knockout animals (Beverdam et al., 2002; Depew et al., 2002; Martin et al., 1995; Yanagisawa et al., 2003) . We show that Dlx5, Dlx6, and Hand2 expression are dramatically reduced in Mef2c NC knockout embryos, and we present evidence that MEF2C is a direct transcriptional regulator of Dlx5/6 via a novel branchial arch enhancer. Additionally, we show that Mef2c and Dlx5/6 genetically interact and that MEF2C functions as a transcriptional partner with Dlx5 in a feed-forward transcriptional circuit by synergistically activating a novel branchial enhancer in the Dlx5/6 locus ( Figure 4D ).
Modular Control of Branchial Arch Gene Regulation
It has been noted previously that deletion of the Hand2 branchial arch enhancer does not completely abolish Hand2 expression in the branchial arches, as a small region of distal expression within the arches appears to be governed by a hypothetical, unidentified regulatory element (Charite et al., 2001; Ruest et al., 2004; Yanagisawa et al., 2003) . Interestingly, the loss of Hand2 expression seen in the absence of Mef2c function in the NC is nearly complete, except at the distal end of the first arch, which appears to correspond to the Dlx6-independent Hand2 expression domain ( Figure 2H ) . Thus, Hand2 regulation, even within the branchial arches, appears to be controlled by multiple enhancer modules (Charite et al., 2001; Ruest et al., 2004; Yanagisawa et al., 2003) . Similarly, a previously identified intergenic Dlx5/6 enhancer directs expression to the forebrain and to a subset of the endogenous Dlx5 and Dlx6 expression (C-H) Dlx5, Dlx6, and Hand2 expression are nearly absent in the branchial arches of Mef2c neural crest knockout embryos at E9.5. Note that (F) Dlx6 expression is still faintly detected in the first arch of Mef2c neural crest knockout embryos, and that (D and H) Dlx5 and Hand2 expression appears to be absent, except in a small region at the distal tip of the first arch. (I and J) X-Gal staining of E9.5 embryos generated by crossing a ROSA26R lacZ reporter allele into the Mef2c conditional knockout background showed no obvious defects in neural crest contribution to the branchial arches or craniofacial mesenchyme compared to littermate controls. Red arrowheads mark the first branchial arch in all panels; asterisks mark craniofacial ectomesenchymal expression. patterns in the branchial arches (Ruest et al., 2003; Zerucha et al., 2000) . Here, we identify an additional regulatory module immediately upstream of the proposed Dlx6 transcriptional start site that regulates expression in the branchial arches (Figure 3 ). This type of compartmentalized regulation provides the opportunity for independent control of gene expression in discrete lineages or for the intersection of multiple, different upstream pathways in the same lineage.
MEF2C as a Potential Downstream Effector of Endothelin Signaling
Dlx6 and Hand2 expression in branchial arch NC requires endothelin signaling (Charite et al., 2001; Clouthier et al., 2000; Ruest et al., 2004; Thomas et al., 1998) . Endothelin signaling regulates a diverse array of normal developmental and physiological processes, including cardiovascular and craniofacial development in the embryo and vascular tone postnatally ; Kedzierski and Developmental Cell MEF2C Is Required for Craniofacial Development Kurihara et al., 1994) . Endothelin signaling is also critical in a number of pathological processes as well, including hypertension, atherosclerosis, and pathological cardiac hypertrophy and heart failure (Kedzierski and Yanagisawa, 2001) . Targeted inactivation of any one of several endothelin pathway components, including Edn1, Ednra, and Ece1, results in lethality at birth due to craniofacial defects and mechanical asphyxiation. These phenotypes are similar to those exhibited by Mef2c NC knockout mice and also include loss of Dlx6 and Hand2 expression (Charite et al., 2001; Clouthier et al., 1998 Clouthier et al., , 2000 Kurihara et al., 1994; Ruest et al., 2004; Thomas et al., 1998; Yanagisawa et al., 1998) .
Based on these observations, it will be interesting to determine if MEF2C functions as a downstream effector of endothelin signaling during craniofacial development ( Figure 4D ).
Implications for MEF2C Involvement in Congenital Craniofacial Defects
Craniofacial defects are among the most common serious congenital anomalies in humans, affecting as many as 1 in every 300 births (Stanier and Moore, 2004) . However, the affected genes and developmental mechanisms underlying the majority of craniofacial disorders remain unknown (Stanier and Moore, 2004) . This is likely due to the fact that many craniofacial anomalies with a genetic component are highly variable in penetrance or severity, several present as part of broader syndromes, and some craniofacial defects are thought to result from combinations of environmental and genetic influences (Farlie et al., 2004; Stanier and Moore, 2004) . For example, Pierre Robin sequence (PRS) is characterized by hypoplastic mandible, a cleft palate, and obstruction of the upper airway by the tongue (Dinwiddie, 2004; Farlie et al., 2004) . The etiology of PRS is thought to be primarily environmental in nature, although there is evidence for a genetic component to this complex and to broader syndromes that include the PRS phenotypes (Dinwiddie, 2004; Farlie et al., 2004) . Mice lacking Mef2c function in the NC appear to have a similar set of defects in the oral cavity, including a small lower jaw, a cleft palate, and displacement of the tongue, suggesting the possibility that developmental processes regulated by MEF2C may contribute to this or other similar craniofacial defects in humans.
EXPERIMENTAL PROCEDURES
Cloning and Mutagenesis
The Dlx6 enhancer fragment described in these studies was amplified from mouse genomic DNA by using the primers Dlx6-F, 5 0 -CCACCAC ACAAGCTTGCTACCCCACAC-3 0 , and Dlx6-R, 5 0 -TGTGTTCAGAAGC AGGGGCCCTAG-3 0 , and were then cloned into plasmids Hsp68-lacZ and pTK-b-gal for transgenic and transfection analyses, respectively. Mutagenesis was performed as described previously (Dodou et al., 2003) . The sequences of the mutagenic oligonucleotides and other oligonucleotides used for cloning are available upon request.
Transgenic Mice
Transgenic mice were generated by oocyte microinjection by using standard methods (Hogan et al., 1994) as described previously (Dodou et al., 2003) . Mef2c mutant mice carrying the Mef2c flox allele and the conventional knockout allele, Mef2c
Tm1 , have each been described (Lin et al., 1997; Vong et al., 2005) . Wnt1-Cre, Dlx5/6 +/À , and Rosa26R lacZ reporter mice have also each been described (Danielian et al., 1998; Depew et al., 2002; Soriano, 1999) . Transgenic and knockout alleles were detected by Southern blot. All experiments with animals complied with federal and institutional guidelines and were reviewed and approved by the University of California, San Francisco, Institutional Animal Care and Use Committee.
X-Gal Staining, In Situ Hybridization, and Skeleton Preparations X-Gal staining to detect b-galactosidase expression was performed as described previously (Dodou et al., 2003) . In situ hybridization was performed according to standard methods by using digoxigenin-labeled antisense probes as described previously (Rojas et al., 2005) . Skeleton +/À mice were crossed to Dlx5/6 +/À mice, and the total number of offspring was scored on P0 (''# born''). Among the total of each genotype born, animals were scored as either alive and viable (''# alive'') or as dead or clearly cyanotic and dying (''# dead/dying''). Nearly all wild-type, Mef2c
, and Dlx5/6 +/À mice were viable at birth. 
Developmental Cell
MEF2C Is Required for Craniofacial Development and cartilage preparations were performed according to standard procedures (Hogan et al., 1994) .
Cell Culture and Transfections 3T3 cells were maintained in DMEM supplemented with 10% FBS. Transfections were performed with FuGene 6 (Roche), according to the manufacturer's recommendations, in 35 mm dishes. A total of 1 mg each of reporter and expression plasmid was used in each transfection so that the quantity of DNA was always held constant at 2 mg per sample. Cells were cultured for 48 hr after transfection, harvested, and assayed by using the Luminescent b-gal Detection System (Clontech), as described previously (Dodou et al., 2003) . Plasmid pRK5-MEF2C contains the mouse MEF2C cDNA in the pRK-5 mammalian expression vector (BD PharMingen). Plasmid pRK5-MEF2C-VP16 is the same, except that the Herpesvirus VP16 activation domain has been fused in-frame to the C terminus of the MEF2C coding sequence.
Supplemental Data
Supplemental Data include additional analysis of Dlx6 and Hand2 expression and analyses of Prx1 expression, apoptosis, and proliferation in Mef2c conditional knockout and control animals and are available at http://www.developmentalcell.com/cgi/content/full/12/4/645/ DC1/.
